Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


161

projects in our pipeline

10

new molecular entities in our late-stage pipeline

1

new molecular entity approval in the last quarter



Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

Filter By:

Oncology (as at 25 July 2019)

Phase I

Phase I

  • AZD1390 glioblastoma
  • AZD4573 haematalogical malignancies
  • AZD5153 solid tumours
  • AZD5991 haematalogical malignancies
  • AZD9496 oestrogen receptor +ve breast cancer
  • AZD9833 oestrogen receptor +ve breast cancer
  • Calquence + AZD6738 haematological malignancies
  • Calquence + danvatirsen haematological malignancies
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + CTx 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • MEDI1191 solid tumours
  • MEDI2228 multiple myeloma
  • MEDI5083 solid tumours
  • MEDI5752 solid tumours
  • MEDI7247 haematological malignancies, solid tumours
  • oleclumab solid tumours
  • oleclumab + AZD4635 EGFRm NSCLC
  • oleclumab + Tagrisso EGFRm NSCLC

Phase II

Phase II

  • (oleclumab+CTx) or (Imfinzi+oleclumab+CTx) metastatic pancreatic cancer
  • AZD2811 solid tumours
  • AZD4635 solid tumours
  • Imfinzi + (oleclumab or monalizumab) COAST non small cell lung cancer
  • Imfinzi + (oleclumab or monlizumab or danvatirsen) NeoCOAST non small cell lung cancer
  • Imfinzi + AZD5069 or Imfinzi + danvatirsen head and neck squamous cell carcinoma, bladder and NSCLC
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • Lynparza + AZD6738 or Lynparza + adavosertib VIOLETTE breast cancer
  • Lynparza + Imfinzi MEDIOLA ovarian cancer, breast cancer, gastic cancer and small-cell lung cancer
  • Lynparza + adavosertib solid tumours
  • Tagrisso + or selumetinib or savolitinib) TATTON advanced EGFRm non-small cell lung cancer
  • Tagrisso + savolitinib SAVANNAH advanced EGFRm non-small cell lung cancer
  • adavosertib ovarian cancer, solid tumours
  • capivasertib breast cancer, prostate cancer
  • trastuzumab deruxtecan (DS-8201) HER2-expressing advanced colorectal cancer
  • trastuzumab deruxtecan (DS-8201) HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer

Phase III

Phase III

  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + CRT ADRIATIC LD-SCLC
  • Imfinzi + tremelimumab + CTx POSEIDON 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Lumoxiti 3rd-line hairy cell leukaemia
  • Lynparza + Imfinzi + bevacizumab DUO-O 1st-line ovarian cancer
  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • savolitinib SAVOIR papillary renal cell carcinoma
  • selumetinib SPRINT paediatric neurofibromatosis type-1
  • trastuzumab deruxtecan (DS-8201) DESTINY-Breast02 HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1
  • trastuzumab deruxtecan (DS-8201) DESTINY-Breast04 HER2-low, unresectable and/or metastatic breast cancer subjects
  • trastuzumab deruxtecan (DS-8201) DESTINY-Breast01 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
  • trastuzumab deruxtecan (DS-8201) DESTINY-Breast03 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • trastuzumab deruxtecan (DS-8201) DESTINY-Gastric01 HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens

LCM Projects

LCM Projects

  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ELEVATE-RR relapsed/refractory chronic lymphocytic leukaemia, high risk
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Calquence + venetoclax + obinutuzumab 1st-line chronic lymphocytic leukaemia
  • Imfinzi CALLA locally-advanced cervical cancer
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi PACIFIC locally advanced (stage III) NSCLC
  • Imfinzi solid tumours
  • Imfinzi PEARL 1st-line non-small cell lung cancer
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) NSCLC
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) NSCLC
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage III) NSCLC
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellar carcinoma
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellar carcinoma
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Lynparza PROfound prostate cancer
  • Lynparza SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Lynparza (basket) MK-7339-002 / LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Lynparza + cediranib CONCERTO recurrent platinum-resistant ovarian cancer
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso FLAURA 1st-line advanced EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage 3 EGFRm non-small cell lung cancer

Cardiovascular, Renal and Metabolism (as at 25 July 2019)

Phase I

Phase I

  • AZD8233 CV disease
  • AZD9977 CV disease
  • MEDI6570 cardiovascular disease
  • MEDI7219 type-2 diabetes

Phase II

Phase II

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease
  • AZD8601 cardiovascular disease
  • MEDI5884 cardiovascular disease
  • MEDI6012 cardiovascular disease
  • cotadutide type-2 diabetes and obesity
  • verinurad chronic kidney disease

Phase III

Phase III

  • Epanova severe hypertriglyceridaemia
  • Lokelma hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

LCM Projects

LCM Projects

  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique THEMIS cardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke
  • Bydureon EXSCEL type-2 diabetes outcomes study
  • Bydureon BCise (autoinjector) type-2 diabetes
  • Epanova STRENGTH cardiovascular outcomes study in statin-treated patients at high cardiovascular risk, with persistent hypertriglyceridemia plus low HDL-cholesterol
  • Farxiga/Forxiga DECLARE- TIMI 58 cardiovascular outcomes trial in patients with type-2 diabetes
  • Farxiga/Forxiga DELIVER worsening HF or CV death in patients with chronic heart failure (HFpEF)
  • Farxiga/Forxiga DEPICT type-1 diabetes
  • Farxiga/Forxiga DETERMINE-Preserved heart failure with preserved ejection fraction (HFpEF)
  • Farxiga/Forxiga DETERMINE-Reduced heart failure with reduced ejection fraction (HFrEF)
  • Farxiga/Forxiga Dapa-CKD renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga Dapa-HF worsening heart failure or cardiovascular death in patients with chronic heart failure (HFrEF)
  • Qternmet XR (saxagliptin/dapagliflozin metformin) type-2 diabetes
  • Xigduo XR/Xigduo type-2 diabetes
  • roxadustat anaemia in myelodysplastic syndrome

Respiratory (as at 25 July 2019)

Phase I

Phase I

  • AZD0449 asthma
  • AZD1402 asthma
  • AZD5634 cystic fibrosis
  • AZD8154 asthma
  • MEDI3506 chronic obstructive pulmonary disease

Phase II

Phase II

  • AZD1419 asthma
  • AZD7594 asthma/chronic obstructive pulmonary disease
  • AZD7986 chronic obstructive pulmonary disease
  • AZD8871 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • PT010 asthma
  • abediterol asthma/chronic obstructive pulmonary disease
  • tezepelumab atopic dermatitis

Phase III

Phase III

  • Bevespi Aerosphere (PT003) chronic obstructive pulmonary disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE severe uncontrolled asthma
  • PT010 chronic obstructive pulmonary disease
  • PT027 asthma
  • tezepelumab NAVIGATOR SOURCE severe uncontrolled asthma

LCM Projects

LCM Projects

  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra OSTRO nasal polyposis
  • Fasenra chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma

Other (as at 25 July 2019)

Phase I

Phase I

  • AZD0284 psoriasis/respiratory
  • MEDI0700 systemic lupus erythematosus
  • MEDI1341 parkinson's disease
  • MEDI1814 alzheimer’s disease

Phase II

Phase II

  • MEDI3902 prevention of nosocomial Pseudomonas aeruginosa pneumonia
  • MEDI7352 osteoarthritis pain and painful diabetic neuropathy
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • suvratoxumab prevention of nosocomial Staphylococcus aureus pneumonia

Phase III

Phase III

  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

  • Linzess irritable bowel syndrome with constipation (IBS-C)
  • Nexium stress ulcer prophylaxis

Terminations

  • Lynparza + AZD6738 gastric cancer
  • MEDI3726 prostate cancer

Veeva ID: Z4-12937     
Date of next review: September 2020